Partners and distributors
Bring Digistain Breast to the clinicians you serve
Give the oncologists you serve recurrence-risk results usually within 1–2 days of receipt, backed by a peer-reviewed 801-patient validation, with Digistain’s training and support behind you.
Availability
Where Digistain Breast is available
[MARKETS TO CONFIRM]
United Kingdom: UKCA-marked (self-declared), CE-marked under the IVDD, and registered with the MHRA.
European Union: CE-marked under the IVDD. IVDR Class C conformity assessment in progress with notified body QMD Services (2962).
United States: Not currently available in the US.
Other markets: [STATUS PER MARKET]
What partners receive
Everything you need to sell and support the test
Regulatory status
The approved regulatory status statement for your market.
Approved materials
Clinician leave piece, patient brochure and hospital presentation.
Evidence pack
The Breast Cancer Research and Treatment 2024 paper, a one-page plain summary and the standard wording sheet.
Onboarding training
On the test, specimen requirements and approved claims. [FORMAT AND DURATION TO CONFIRM]
Clinician webinars
Digistain presents; the partner hosts. [FREQUENCY TO CONFIRM]
A named contact
For reviewing anything you want to publish. [CONTACT AND TURNAROUND TO CONFIRM]
Partners may publish only Digistain-approved material. Anything else needs Digistain’s written approval before use.
Partner enquiry
Talk to us about your market
Tell us where you operate and the clinicians you serve.